CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: In contrast, there was no difference in G0S2 expression comparing CD34+ BM cells from healthy volunteers with that of CP‐CML patients who reached major molecular remission during imatinib therapy (GDS838, Figure S1D).38